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Comments on “Growth hormone (GH)-releasing hormone 
and GH secretagogues in normal aging”
This issue of Clinical Interventions in Aging contains a quite interesting and informa-
tive article about a topic that is popular and also controversial among practitioners of 
age-management medicine. Appropriate to that controversy, Drs Hersch and Merriam 
(2008) have asked the question in the title of their paper, does the use of growth hormone 
secretagogues in age management medicine hold the promise of a fountain of youth, 
or that of a pool of Tantalus? While there is universal understanding of the fountain 
imagery, the meaning of the pool is perhaps less obvious. It derives, of course, from 
the Greek myth of Tantalus, who had both a hidden, divine sire and a mortal one. As 
the son of Zeus, he was uniquely favored among mortals and was invited to share the 
food of the gods. However, driven by pride, he shared the divine ambrosia with other 
mortals, and thus aroused the ire of the gods. As punishment, he was made to stand 
chin-deep in water with a variety of sweet-smelling and delicious fruit dangling just 
over his head. However, whenever he tried to drink or eat, the water would magically 
recede or the fruit would miraculously be lifted just out of his reach. Thus, it is that 
torment, through which something seems to be offered only to be withdrawn again, 
that has been called “tantalizing” in memory of its best known victim.
The authors’ comments about these images at the paper’s end indicate that they 
had already formed an opinion of which better represents the relationship of GH secre-
tagogues to age management therapies. In those comments, they suggest that while 
beneﬁ  cial, secretagogue therapy as currently employed hardly brings youthful rejuve-
nation and that the expectations of efﬁ  cacy are more tantalizing than realizable. While 
most practitioners would agree that growth hormone replacement therapy (GHRT) will 
not restore youth, I feel that its effects are more than tantalizing since by deﬁ  nition the 
word describes that which is desired but unattainable. Thus, the description provided 
of the pool of Tantalus seems to deﬁ  ne the use of secretagogues as a fantasy therapy 
that is ineffective in providing actual beneﬁ  t. However, it should be remembered that 
Tantalus can also be seen as a Promethian ﬁ  gure. Recall that Prometheus was a Titan 
credited with (or blamed for) playing a pivotal role in the early history of humankind 
by divulging divine secrets to mortals. This alternative image of Tantalus, linked to 
his sharing of ambrosia with other mortals would be more positive when associated 
with the use of GH secretagogues in age management. In any event, without further 
second guessing of the authors’ intentions through symbolism, I congratulate them 
in providing an unbiased and comprehensive review of the current status of the sub-
ject that provides an invaluable reference guide to practitioners of age-management 
medicine who incorporate GHRT into their clinical practice.
Drs. Hersch and Merriam initiate the paper with a succinct review of the GH 
neuroendocrine axis including presumptive involvement of ghrelin. Included is a 
diagram proposing possible ghrelin feedback relationships within the axis and also GH 
independent actions of the secretagogue. The practical relevance of this information 
is that there are two ghrelin analogs, GHRP-2 and GHRP-6, currently being marketed 
as dietary supplements. A brief inspection of the dosages used and knowing that 
they are orally bioavailable indicates that these products are efﬁ  cacious in releasing 
endogenous GH. In fact, I received reports from several practitioners indicating that 
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buffering against overdose. Finally, since the ghrelin analogs 
are smaller molecules than hGH or even the GHRH analog 
sermorelin, they can be administered orally, transdermally, 
or nasally. As mentioned above, dietary supplements for 
GHRP-2 and GHRP-6 are currently available and may have 
valuable clinical application.
In conclusion, I would agree that while there is a paucity 
of data on the use of secretagogues in age-management 
medicine, this review brings together nicely that which is 
currently published. As part of their professional obligations, 
practitioners should strive to increase this base of knowledge 
by measuring and reporting outcomes of treatments offered 
at their clinics so that the beneﬁ  ts and risks can be accurately 
assessed. In support of this effort, the Society for Applied 
Research in Aging is offering to create such a database with 
help of all practitioners willing to participate. To facilitate the 
effort, guidelines, data collection forms, statistical analytical 
services and publication of the outcomes are offered as a 
service to the clinical community. To learn more about this 
data registry go to www.ageresearchsociety.com.
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they elicit signiﬁ  cant GH release and increase IGF-1. If true, 
this fact makes their use either alone or in conjunction with 
sermorelin, the only commercially available GHRH analog, 
practical for clinical application. Since the combination is 
very synergistic, its use in individuals who are relatively 
insensitive to GHRH alone may be of signiﬁ  cant interest.
The authors then transition to a comparison of the clinical 
consequences of adult growth hormone deﬁ  ciency (AGHD), 
a pathologic condition, and the age-associated decrease in 
production and secretion of somatotropin. They point out that 
while the etiologies of the two conditions differ signiﬁ  cantly, 
they share many clinical similarities that differ basically by 
degree. Furthermore, replacement therapy with recombinant 
hGH seems to have a broader spectrum of efﬁ  cacy and safety 
in younger individuals suffering AGHD than in the elderly. 
In this regard, the secretagogues which produce a more 
physiological proﬁ  le of growth hormone secretion are more 
appropriate as interventions in aging than recombinant hGH 
because they restore function in more components of the neu-
roendocrine axis including feedback relationships and thus, 
are less likely to cause side effects. They further point out 
that the effects of ghrelin analogs are inﬂ  uenced by the same 
factors that modulate endogenous GHRH secretion, such 
as negative feedback by somatostatin providing additional 